Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>UNC669

UNC669

Catalog No.GC18096

UNC669, un ligando para un dominio de unión de metil-lisina, es un potente inhibidor de L3MBTL1 (IC50 \u003d 4,2 uM) y L3MBTL3 (3,1 uM).

Products are for research use only. Not for human use. We do not sell to patients.

UNC669 Chemical Structure

Cas No.: 1314241-44-5

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
64,00 $
Disponible
10mg
52,00 $
Disponible
25mg
84,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

UNC 669 is a potent antagonist of L3MBTL1 (IC50=4.2 μM) and L3MBTL3 (IC50=3.1 μM).

There is less bio-data supported for UNC669. UNC1679 is an analog of UNC669. UNC1215 is the first potent and selective antagonism of a methyl-lysine reader protein, L3MBTL3, which antagonizes the mono- and dimethyl-lysine reading function of L3MBTL3. [1]

Lysine methylation is a key epigenetic landmark, the dysregulation of which is related to many diseases. UNC1679 maintains in vitro and cellular potency with improved selectivity against other MBT-containing proteins. The antagonists described were also found to effectively interact with unlabeled endogenous L3MBTL3 in cells. [1]

Reference:
1.  James LI, Korboukh VK, Krichevsky L et al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem. 2013 Sep 26;56(18):7358-71. doi: 10.1021/jm400919p. Epub 2013 Sep 16.

Reseñas

Review for UNC669

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for UNC669

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.